West Pharmaceutical Services (WST) Stock Could Be 6.9% Undervalued on GLP 1 Growth Narrative

June 22, 2026 - 04:41

West Pharmaceutical Services (WST) stock has drawn attention after recent share price moves, with investors weighing its role in drug containment and delivery in relation to current valuation signals and recent returns over the past month and past three months. At a share price of $327.95, West Pharmaceutical Services has seen strong momentum build over the past quarter, with a 35.85% three-month share price return and a 52.46% one-year total return.

The company, known for its components used in injectable drug packaging, is increasingly tied to the booming GLP-1 receptor agonist market. These drugs, used for diabetes and weight loss, require specialized containment and delivery systems, a niche where West Pharmaceutical holds a strong position. Analysts suggest this growth narrative could mean the stock is roughly 6.9% undervalued at current levels.

While the broader market has been volatile, West Pharmaceutical's recent performance reflects optimism around its exposure to high-demand therapeutic areas. The company's components are critical for the safe storage and administration of these injectable medications, making it a key indirect beneficiary of the GLP-1 wave. Investors are now watching to see if the stock can sustain its upward trajectory as earnings reports and product demand updates emerge in the coming quarters.